Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSheba Medical Center
About this trial
This observational study evaluates if ex-vivo lung cancer drug sensitivity testing results correlate with the driver mutations found by genetic sequencing and if it can predict treatment response.
Eligibility criteria
Qualifiers
Presence of pleural effusion in patient with a diagnosis of a lung cancer or suspected to be diagnosed with lung cancer according to their CT imaging, who are in need for pleural effusion drainage due to shortness of breath, and are willing to donate effusion for ex-vivo drug sensitivity testing.
Patient's written informed consent present.
Ability to understand the nature of the trial and the trial related procedures and to comply with them.
Disqualifiers
negative cytology for malignancy in the last 6 months
Trial design
Treatments tested in this trial
- Non-Interventional Study
Treatment groups
400 Participants
are divided into 1 treatment groupLocations
1Sheba Medical Center5262100, Ramat GanIsrael, Israel
Sponsors and collaborators
Sheba Medical Center
Lead sponsor
Source ClinicalTrials.gov